Jazz Pharmaceuticals, Inc.
NEWS
CEL-SCI Corporation, Jazz Pharmaceuticals, CARsgen and Ascentage Pharma presented clinical trial data at the American Society of Clinical Oncology 2022 Annual Meeting.
BioSpace looks at the challenges faced by the Latinx community in the life sciences, from the origins of the challenges, to educational gain and the importance of mentorship.
Jazz’s Q1 included a key licensing deal with Werewolf Therapeutics and another announced Wednesday with Japan’s Sumitomo Pharma Co. for a narcolepsy treatment.
Shares of Axsome Therapeutics have fallen more than 20% in trading this morning after the company announced the FDA is unlikely to approve its acute migraine treatment AXS-07 due to unresolved quality control issues.
The acquisition of Sunosi transforms Axsome into a global commercial business that will support its operations as it moves closer to launching its treatments for depression and migraine.
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
The Phase II trial is evaluating zepzelca as a monotherapy in patients with urothelial carcinoma, large cell neuroendocrine carcinoma of the lung and HRD tumors.
Aria Pharmaceuticals is using a unique computational approach to drug development that has increased its success rate by 30-fold when compared to traditional approaches.
The company’s vision for the next few years includes annual revenue of $5 billion by 2025 and the approval of at least five novel products by the end of the decade.
JOBS
IN THE PRESS